Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maze Therapeutics Inc (MAZE)

Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,396,326
  • Shares Outstanding, K 49,709
  • Annual Sales, $ 0 K
  • Annual Income, $ -131,120 K
  • EBIT $ -143 M
  • EBITDA $ -141 M
  • 60-Month Beta 5.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.64

Options Overview Details

View History
  • Implied Volatility 84.41% (-11.24%)
  • Historical Volatility 134.15%
  • IV Percentile 25%
  • IV Rank 8.76%
  • IV High 228.70% on 03/10/26
  • IV Low 70.56% on 12/22/25
  • Expected Move (DTE 26) 4.63 (16.49%)
  • Put/Call Vol Ratio 0.58
  • Today's Volume 49
  • Volume Avg (30-Day) 255
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 5,780
  • Open Int (30-Day) 5,429
  • Expected Range 23.46 to 32.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.43
  • Number of Estimates 6
  • High Estimate $-0.32
  • Low Estimate $-0.70
  • Prior Year $-1.15
  • Growth Rate Est. (year over year) +62.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.16 +7.38%
on 04/10/26
51.74 -45.71%
on 03/18/26
-22.30 (-44.25%)
since 03/17/26
3-Month
26.16 +7.38%
on 04/10/26
53.65 -47.64%
on 03/16/26
-12.68 (-31.10%)
since 01/16/26
52-Week
7.16 +292.32%
on 04/25/25
53.65 -47.64%
on 03/16/26
+19.68 (+234.01%)
since 04/17/25

Most Recent Stories

More News
U.S. Jobs Figures Issued in Short Week

MondayFeatured Earnings Maze Therpautics (NASDAQ:MAZE) (Q4) EPS for loss of 73 cents, compared ...

AYI : 292.63 (+3.31%)
MKC : 54.33 (+1.99%)
FDS : 232.73 (+0.38%)
MSM : 97.52 (+3.56%)
CAG : 14.86 (+1.09%)
NKE : 46.03 (+0.72%)
PRGS : 30.93 (+3.72%)
POET : 7.26 (-1.09%)
LW : 44.82 (+2.52%)
ANGO : 10.86 (+3.82%)
MAZE : 28.09 (+4.54%)
LNN : 108.29 (+1.77%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 28.09 (+4.54%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 28.09 (+4.54%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 28.09 (+4.54%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 28.09 (+4.54%)
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 28.09 (+4.54%)
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 28.09 (+4.54%)
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 28.09 (+4.54%)
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate...

MAZE : 28.09 (+4.54%)
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 28.09 (+4.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif....

See More

Key Turning Points

3rd Resistance Point 31.12
2nd Resistance Point 29.90
1st Resistance Point 29.00
Last Price 28.09
1st Support Level 26.87
2nd Support Level 25.65
3rd Support Level 24.75

See More

52-Week High 53.65
Fibonacci 61.8% 35.89
Fibonacci 50% 30.41
Last Price 28.09
Fibonacci 38.2% 24.92
52-Week Low 7.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.